Dasatinib inhibits tyrosine-kinases including cKIT and EPH, and is approved for the treatment of chronic myeloid leukemia and acute lymphatic leukemia [36, 37]. This evidence concerns the gene KIT and chronic myelogenous leukemia, BCR-ABL1 positive.